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Abstract
Orexins are neuro-modulatory peptides involved in the control of diverse physiological functions through interaction with
two receptors, orexin-1 (OX1R) and orexin-2 (OX2R). Recent evidence in pre-clinical models points toward a putative
dichotomic role of the two receptors, with OX2R predominantly involved in the regulation of the sleep/wake cycle and
arousal, and the OX1R being more specifically involved in reward processing and motivated behaviour. However, the
specific neural substrates underlying these distinct processes in the rat brain remain to be elucidated. Here we used
functional magnetic resonance imaging (fMRI) in the rat to map the modulatory effect of selective OXR blockade on the
functional response produced by D-amphetamine, a psychostimulant and arousing drug that stimulates orexigenic activity.
OXR blockade was produced by GSK1059865 and JNJ1037049, two novel OX1R and OX2R antagonists with unprecedented
selectivity at the counter receptor type. Both drugs inhibited the functional response to D-amphetamine albeit with distinct
neuroanatomical patterns: GSK1059865 focally modulated functional responses in striatal terminals, whereas JNJ1037049
induced a widespread pattern of attenuation characterised by a prominent cortical involvement. At the same doses tested
in the fMRI study, JNJ1037049 exhibited robust hypnotic properties, while GSK1059865 failed to display significant sleep-
promoting effects, but significantly reduced drug-seeking behaviour in cocaine-induced conditioned place preference.
Collectively, these findings highlight an essential contribution of the OX2R in modulating cortical activity and arousal, an
effect that is consistent with the robust hypnotic effect exhibited by JNJ1037049. The subcortical and striatal pattern
observed with GSK1059865 represent a possible neurofunctional correlate for the modulatory role of OX1R in controlling
reward-processing and goal-oriented behaviours in the rat.
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Introduction
Orexins (hypocretins) are neuropeptides synthesized in the central
nervous system by hypothalamic neurons [1]. Orexin-containing
neurons interact with major modulatory neurotransmission systems
and have been implicated in a wide range of physiological functions
including feeding, arousal and sleep, neuroendocrine function,
autonomic control and reward-processing [2–6]. Two orexin
receptors (OX1R and OX2R) have been identified with distinct
and largely complementary patterns of expression in the brain [7].
Recent pharmacological data and phenotypic characterisation of
mice with genetic alterations of the orexin system point towards a
possible functional specialization for the two receptor subtypes.
Specifically, genetic and behavioural research has highlighted a role
for the OX2R in the regulation of sleep/wake cycle and energy
homeostasis [2,3,8,9], while recent neuro-anatomical and pharma-
cological results suggest a putative contribution of the OX1R in
modulating motivated behaviour and reward function [2,10,11].
A number of pharmacological tools have been developed to
help investigate OXR function in vivo, and preliminary clinical
assessment of the therapeutic potential of dual OX1R-OX2R
antagonists for the treatment of insomnia have produced
promising results [12,13]. However, the limited selectivity of the
OXR antagonists available has prevented a full elucidation of the
relative neuro-functional contribution of each receptor sub-type on
specific physiological functions of potential therapeutic relevance.
Moreover, little is known of the circuital substrates modulated by
the two receptors in vivo, and the relationship of these with specific
behavioural outcomes.
In order to begin to address these questions, we used
pharmacological magnetic resonance imaging (phMRI) to spatial-
ly-resolve the circuitry modulated by selective OXR antagonism in
the rat brain. OX2R blockade was produced by using
JNJ10397049 [9,14], a recently described potent and selective
OX2R antagonist, while OX1R blockade was induced with the
novel OX1R antagonist GSK1059865 (5-bromo-N-[(2S,5S)-1-(3-
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2-amine) [15]. We show that the two compounds exhibit
unprecedented selectivity ($100-fold) over the counter receptor
sub-type and display favourable pharmacokinetic properties which
make them ideally-suited for in vivo rodent studies. The imaging
studies were performed using the psychostimulant D-amphetamine
to stimulate orexigenic activity [16,17] and thus amplify the
modulatory effect of OXR blockade independently of tonic levels
of orexigenic activity. Finally, in an attempt to identify putative
behavioural correlates of the imaging findings, the two compounds
were tested in behavioural measures of sleep and reward-
processing at the same doses used in the imaging experiments.
Results
In vitro potency and selectivity
Both GSK1059865 and JNJ10397049 antagonised, in a concen-
tration dependent manner, Orexin-A-induced [
3H] Inositol Phos-
phates (IP)accumulation (N=3) inRBL cellsstablyexpressing either
rat OX1R or OX2R. GSK1059865 and JNJ10397049 displayed a
non-surmountable antagonism of Orexin-A with depression of the
agonist maximal response at OX1R. The pKB values were 8.8
(CI95% 8.7–9.1) and 5.9 (CI95% 5.8–6.1) for GSK1059865 and
JNJ10397049, respectively. On the contrary, the antagonism of the
two compounds at OX2R was surmountable with a right shift of the
agonist concentration response curve without depression of the
maximal effect. The pKB values were 6.9 (CI95% 6.8–7.0) and 8.5
(CI95% 8.3–8.6) for GSK1059865 and JNJ10397049, respectively.
The potency values obtained for JNJ10397049 are consistent with
previously published pKi data [5.7 and 8.2, respectively, 14]. The
same authors reported no significant affinity of JNJ10397049 in a
panel of more than 50 other neurotransmitters and neuropeptide
receptors (,50% inhibition at 1 mM, [14]). Likewise, GSK1059865
did not highlight significant affinity (,50% inhibition at 1 mM) over
a panel of 113 receptors with the exception of k-opioid (KOP)
receptor for which GSK1059865 has a pKi of 6.5, corresponding to
a selectivity of approximately 300 fold versus OX1R.
Pharmacokinetic parameters and dose selection
In order to identify a suitable dose of GSK1059865 for the
imaging studies, we measured pharmacokinetic parameters of the
compound upon intraperitoneal administration, and used these to
estimate the corresponding theoretical brain receptor occupancies.
Pharmacokinetic analysis showed that the compound is brain
penetrant (Brain:Blood ratio was ,0.3) and that intraperitoneal
administration ensures ample and sustained systemic exposure.
Based on the pharmacokinetic data and orexin receptor potencies,
we estimated that a dose of 30 mg/kg of GSK1059865 corresponds
to .70% OX1R occupancy while retaining full selectivity (,5%
OX2R) over the counter receptor sub-type (Figure 1). These values
make this dose suited to probe in vivo the role of OX1R blockade
with negligible risk of spurious OX2R contributions.
Pharmacokinetic parameters and ex-vivo OX2R occupancy in
the rat brain of JNJ10397049 have been recently described [9].
Based on these data, for the imaging experiment we selected a
dose of 50 mg/kg, corresponding to an OX2R occupancy higher
than .70%. In the light of the high selectivity of the drug for
OX2R over OX1R (400-fold) negligible receptor occupancy at the
counter receptor sub-type is expected at this dose.
OX1R and OX2R antagonism differentially attenuate the
functional response to D-amphetamine
In order to spatially-resolve the neuronal substrates affected by
selective OX1R or OX2R antagonism in the rat brain, we
mapped the modulatory effect of GSK1059865 and JNJ10397049
in animals challenged with D-amphetamine, a drug that stimulates
orexigenic activity, using phMRI.
Consistent with previous studies [18] D-amphetamine produced
robust, widespread and sustained rCBV increases in cortical and
subcortical regions (Figures 2–4). The effect is unlikely to be
dominated by peripheral blood pressure changes, as these were not
temporally correlated with the rCBV time-course (Figure S2), and
well within the blood flow autoregulatory range within which
vasopressive responses are homeostatically compensated without
producing significant rCBV alterations [19].
Pretreatment with the selective OX1R antagonist GSK1059865
(30 mg/kg i.p) produced a significant attenuation of D-amphet-
amine’s functional response in sub-cortical areas and focal cortical
regions (Z.1.96, Figures 2, 3 and 5). The effect was bilateral and
prominent in the dorso-lateral striatum but extended also to the
fronto-ventral areas of this structure up to the frontal portions of
the shell of the nucleus accumbens (Z.1.96, Figure 5). Among
cortical regions, the insular, cingulate and primary auditory
cortices were the only areas that exhibited significant attenuation
(Figures 3 and 5). Occasional small spots of inhibition were also
observed in the rostral portions of the somatosensory cortex. By
contrast, pretreatment with the selective OX2R antagonist
JNJ10397049 (50 mg/kg i.p) produced a substantially more
widespread pattern of attenuation that included most cortical
regions (Figures 2, 4 and 5), with substantial contributions from
somatosensory, motor, cingulate and orbitofrontal cortices.
Weaker but significant attenuating effects were observed in sub-
cortical nuclei of the thalamus, hypothalamus, and striatum and
hippocampus (Figure 5).
No region showed increased response to D-amphetamine in
animals pre-treated with either GSK1059865 or JNJ10397049.
The lack of potentiating effects cannot be attributed to the use of
an amphetamine dose producing ‘‘ceiling’’ functional effects, as
region-specific potentiation of response by different pharmacolog-
ical mechanisms has been previously described using the same
protocol and dose of D-amphetamine [18,20]. Neither
GSK1059865 nor JNJ10397049 produced substantial rCBV
alterations per se in any of the regions examined (Figures S3 and
Figure 1. Brain receptor occupancy of GSK1059865. Theoretical
brain receptor occupancy for GSK1059865 after intraperitoneal
administration of 30 mg/kg to male SD rats. Data points represent
mean +/2 standard deviation.
doi:10.1371/journal.pone.0016406.g001
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changes induced by either drug.
OX2R but not OX1R antagonism produces robust
sleep-promoting effects
In an attempt to identify a behavioural correlate to the
divergent imaging profile of the two compounds, we measured
the sleep-promoting effect of GSK1059865 and JNJ10397049
when administered at 6 hrs into the dark phase, at time point at
which the Orexin-A peptide is highly expressed [21].
JNJ10397049 showed profound sleep-promoting effects at all
doses tested (5, 25 and 50 mg/kg i.p.). More specifically,
JNJ10397049 substantially increased REM, NREM and total
sleep-time across the whole 5 hour time-window of recording at all
doses tested (Figure 6). Interestingly, the sleep-promoting effects of
JNJ10397049 were not observed with GSK1059865. When tested
at doses similar to those used in phMRI experiment assays
(25 mg/kg i.p.), the compound did not significantly increase REM
and total sleep-time over the 5 hours duration of the experiment,
either as individual 1 hour bins or cumulative five-hour integra-
tion (p.0.16, all parameters, Figures 6), but only produced a small
(,3 min) significant increase in a cumulative measure of total
REM sleep time (p,0.02). At a lower dose (5 mg/kg i.p.) the
compound did not significantly alter any of the sleep parameters
recorded (Figure 6).
OX1R antagonism dose-dependently reduces expression
of cocaine-induced conditioned place preference (CPP)
In order to investigate a possible behavioural correlate of the
striatal phMRI effects observed with GSK1059865, we also tested
the compound in a cocaine-induced conditioned place-preference
(CPP) paradigm. This behavioural test is widely employed to
measure drug-seeking (i.e. a goal-oriented behaviour) in laboratory
animals [22] and crucially involves the recruitment of striatal
dopaminergic areas as effectors of the reward-related processing
underling the preference for the drug-paired chamber [23]. In
keeping with the results obtained by other investigators using less
selective OX1R antagonists [i.e. SB334867, 6,10], GSK1059865
dose-dependently inhibited cocaine-induced place preference, an
effect that reached statistical significance at both 10 and 30 mg/kg
i.p. (Figure 7). JNJ10397049’s robust hypnotic and sedative profile
at doses as low as 3 mg/kg prevented us from testing the drug in
the same paradigm.
Discussion
We have used fMRI to map the functional substrates of OX1R
or OX2R blockade in the rat brain using GSK1059865 and
JNJ1037049, two novel and highly-selective OXR antagonists.
The imaging findings highlighted a different neuroanatomical
pattern of functional inhibition for the two compounds:
GSK1059865 produced focal striatal effects, whereas
JNJ1037049 induced a composite pattern of modulation char-
acterised by a prominent cortical involvement. Moreover, at doses
similar to those tested in the fMRI study, JNJ1037049 exhibited
robust hypnotic properties, whereas GSK1059865 did not display
significant sleep-promoting effects. Collectively, these findings
highlight an essential contribution of the OX2R in modulating
cortical brain function, an effect that correlates with the robust
hypnotic effect exhibited by JNJ1037049. The striatal effect
observed with GSK1059865 represent a putative neurofunctional
correlate for the recognised modulatory role of OX1R antagonism
in reward-processing and goal-oriented behaviour in the rat, an
effect that was confirmed with GSK1059865 in a cocaine-induced
CPP paradigm.
In order to image the effects of OXR antagonism in
anaesthetised animals, we developed a phMRI protocol relying
on the use of the psychostimulant D-amphetamine. The drug
elicits a composite pattern of activation involving cortical
Figure 2. fMRI activation produced by D-amphetamine as a function of pharmacological pre-treatment. Anatomical distribution of the
activation produced by D-amphetamine challenge across the different treatment groups. Yellow/orange indicates increased rCBV versus vehicle-
vehicle baseline (Group 5). OX1Rant: GSK1059865 (30 mg/kg i.p.); Ox2Rant:: JNJ10397049 (50 mg/kg i.p.).
doi:10.1371/journal.pone.0016406.g002
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compound, as well as subcortical regions pivotally involved in
processing of reward and control of motivated behaviour [24].
Moreover, amphetamines robustly activate orexin neurons
[16,17], and can be used to probe the modulatory action of
OXR antagonism independently of tonic levels of orexigenic
activity (i.e. in anaesthetised animals). We used rCBV as surrogate
haemodynamic readout for underlying changes in brain activity
[25,26]. This measure has gained acceptance as the measure of
choice in small animal fMRI studies where sensitivity is a
significant technical challenge [27,28].
The robust sleep-promoting effect of JNJ1037049 is consistent
with recent pharmacological data [9] and with phenotypic
characterisation of mice with genetic alterations of the OX2R
system [2,4]. Our sleep-measurements substantiate the central
role of the OX2R in regulating arousal and the sleep\wake
cycle. Within the framework of a divergent sleep-promoting
effect of JNJ1037049 and GSK1059865, the imaging findings
are of interest as they reveal a predominant contribution of the
OX2R in controlling brain function in broad cortical and sub-
cortical networks, an effect that might be functionally related to
the hypnotic effect exhibited by JNJ1037049. Notably, positron
emission tomography (PET) measurements of cerebral blood
flow during physiological sleep in humans [reviewed in 29] have
consistently shown coordinated inhibition of thalami, basal
ganglia, hypothalamus and large neocortical areas, in a pattern
that is qualitatively very consistent with the inhibition observed
with JNJ1037049 in the present study. Given the rich and
complex interactions between orexin and other neurotransmit-
ter systems [reviewed in 2], the widespread functional inhibition
produced by JNJ1037049 may integrate downstream contribu-
tions of heterogeneous nature that could involve multiple
modulatory neurotransmitters including histamine, serotonin,
noradrenaline, acetylcholine and dopamine. The availability of
Figure 3. fMRI timecourse in representative brain regions: effect of OX1R antagonism. Temporal-profile of amphetamine-induced rCBV
changes in representative VOIs. Data are plotted as mean6SEM within each group. OX1Rant: GSK1059865 (30 mg/kg i.p.) [SS Ctx: somatosensory
cortex; Cpu: caudate putamen; mPFC: medial prefrontal cortex; Ins Ctx; insular cortex; Thal; thalamus; Hipp: hippocampus].
doi:10.1371/journal.pone.0016406.g003
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to promote the investigation of the neurobiological and
therapeutic significance of such interactions in normal and
disease states.
The virtual absence of sleep-promoting effects of the selective
OX1R antagonist GSK1059865 at the doses tested in the present
study (i.e. with negligible OX2R occupancy) provides an
independent confirmation of the pharmacological data reported
by Dugovic et al., [9] showing that blockade of OX2R is sufficient
to initiate and prolong sleep. Previous studies reported on the lack
of significant change in the amount of sleep-wake states after
administration of the OX1R antagonist SB-334867[30]. Taken
together these studies point towards a role for the development of
selective OX2R antagonists as functionally-specific sleep-promot-
ing pharmacological tools.
Separate roles for the two OXR subtypes on sleep architecture
that fit well with their differential distribution have been
postulated; namely, a specific role in the regulation of REM sleep
for OX1R in the locus coeruleus [30] and an implication of
hypothalamic OX2R in the modulation of NREM sleep [4]. The
observation of focal contribution of OX1R in modulating total
REM sleep correlates with electroencephalographic phenotyping
of orexin double-receptor (OX1R and OX2R) knockout which
significantly differs from single OX2R -knockout by a greater
incidence of direct transitions from wakefulness to REM sleep
[4,31]. Our data suggest that pharmacological OX1R may exert
Figure 4. fMRI timecourse in representative brain regions: effect of OX2R antagonism. Temporal-profile of amphetamine-induced rCBV
changes in representative VOIs. Data are plotted as mean6SEM within each group. OX2Rant:: JNJ10397049 (50 mg/kg i.p.) [SS Ctx: somatosensory
cortex; Cpu: caudate putamen; mPFC: medial prefrontal cortex; Ins Ctx; insular cortex; Thal; thalamus; Hipp: hippocampus].
doi:10.1371/journal.pone.0016406.g004
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in presence of a functional OX2R.
An interesting finding of this study is the region-specific
modulation of the striatum and focal cortical terminals observed
with the OX1R antagonist. This pattern contrasts sharply with
widespread and robust cortical deactivation observed with the
OX2R antagonist JNJ1037049. Although the exact neuro-circuital
cascade underlying the divergent imaging findings remains
unknown, several hypotheses can be made in the light of previous
anatomical and functional studies. Firstly, the focal deactivation of
striatal terminals produced by GSK1059865 cam be related to the
existing evidence of the OX1R in the control of reward processing
and drug-seeking. Using a self-administration paradigm, Aston-
Jones and colleagues [6], discovered that pre-treatment with the
OX1R antagonist SB334867 blocks cocaine-seeking induced by
discrete or contextual cues. The same drug significantly attenuated
the expression of a morphine CPP [10]. However, SB334867
possesses micromolar or sub-micromolar affinity at other receptor
types (i.e. adenosine2AR, pKi=7.2; melatonin2Rp K i=6.9,
serotonin2C and norepinephrine transporter pKi=5.7; M. Corsi,
unpublished results) which significantly narrows the selectivity
window (,10-fold) over OX1R (pKB=7.5) and poses questions as
to whether the effects reported so far with SB334867 can be solely
attributed to OX1R antagonism. Our cocaine CPP study with
GSK1059865, a compound of unprecedented OX1R selectivity
and structurally unrelated to SB334867, suggests that OX1R is
sufficient to modulate reward-processing and drug-seeking behav-
iours. Interestingly, the CPP paradigm crucially involves the
recruitment of striatal dopaminergic areas as effectors of the
reward-related processing underling the preference for the drug-
paired chamber [23]. Given the tight correlation between striatal
response to D-amphetamine and local dopamine release [reviewed
in 32], it is therefore tempting to speculate that the striatal
inhibition observed with the OX1R antagonist may represent an
indirect neurofunctional correlate of the ability of GSK1059865 to
reduce expression cocaine-induced CPP. Such an effect would be
consistent with the presence of major orexigenic projections to the
ventral tegmental area [33] as well as the substantia nigra [34] and
with the dramatic increase in orexin firing that has been observed
in association to explorative behaviours [35,36]. Such an
hypothesis would support a theoretical construct where orexin
neurons are strategically positioned at a transitional point where
internally driven states (e.g desire for drugs), are translated into
patterned motor response [37]. Within this framework, the
presence of focal and bilateral deactivation in the insular cortex
in the OX1R antagonist group is of great interest, given the
central role of this structure as integrator of interoceptive states
into conscious feelings and decision-making processes that
precipitate relapse [38]. The involvement of OX1R in these
processes has been recently supported by the results of a recent
study [11] where pharmacological blockade of OX1R receptors in
the insula, but not in the adjacent somatosensory cortex, inhibited
nicotine intake in a self-administration paradigm. Collectively, and
in agreement with the behavioural data, the imaging findings
argue for a targeted modulatory role of the OX1R on
neurobehavioural substrates that may be perturbed in states of
addiction. These features make OX1R an attractive target for the
development of novel pharmacological treatment for these
disorders.
A few cautionary statements should be made about this study.
Whether the circuits identified in the phMRI study underpin the
homeostatic substrates modulated by OXRs, or rather are a
consequence of the hyper-arousal state produced by the D-
amphetamine is an aspect that could not be addressed due to the
need to keep animals under anaesthesia to reduce stress and
motion artefacts. Together with a possible interfering role of
anaesthesia with tonic orexigenic activity, the use of d-amphet-
amine might have resulted in supra-physiological contributions
that may limit the physiological relevance of the imaging findings
to the homeostatic state. As selective orexin antagonists will
become available for clinical investigations, a definite answer to
this question will be provided by neuroimaging studies in
conscious human subjects. It is however unlikely that the imaging
findings reflect major unspecific pharmacological interactions
between the OXR antagonists and the anaesthetic, as these would
be expected to present themselves in the form of detectable rCBV
alterations upon the injection of the pre-treatments per se.
Moreover, halothane anaesthesia has been recently demonstrated
to exert negligible influence on orexigenic activity [39].
In this study we did not measure the ex-vivo receptor occupancy
of GSK1059865 and JNJ1037049 directly, but used estimates
based on PK data and in vitro potencies. However, the high
potency and selectivity of the two drugs argue against a spurious
contribution of the counter-type receptors at the doses used for
these studies. This notion is corroborated by the good correspon-
dence between our behavioural results and those obtained by
other authors under similar dosing regimens [9]. Moreover,
additional imaging experiments performed in our lab with dual
OXR antagonists characterised by different relative affinity at
OX1R and OX2R confirmed the prevalence of cortical and
Figure 5. Attenuation of fMRI response by OX1R or OX2R antagonism. Regions of reduced amphetamine-induced rCBV response following
pre-treatment with GSK1059865 (OX1Rant; top) or JNJ10397049 (OX2Rant, bottom). Blue indicates reduced rCBV response versus control (vehicle-
amphetamine). Cpu: caudate putamen; SS ctx: somatosensory cortex; Ins: insular cortex, AcS: shell of the nucleus accumbens.
doi:10.1371/journal.pone.0016406.g005
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OX1R occupancy, respectively (A. Gozzi, unpublished results).
Another limitation is the use of a single-dose of each compound in
the imaging study, a choice dictated by the complex and time
consuming preparation and monitoring procedures used to ensure
a tight control of animal physiology during the phMRI
experiments. Clearly, an exploration of the imaging effects across
a range of doses would be desirable and would in principle enable
a better appraisal of the relative functional contribution of the two
receptors. However, this would have lengthened the duration of
the experiment considerably, at the expense of the homogeneity of
the experimental groups of animals in terms of age, size and batch,
with potentially detrimental effects. Finally, we point out that a
trend for weak signal attenuation in cortical areas was also
observed with GSK1059865 (Figure 3). Whether this effect is the
result of inter-group statistical fluctuations, non-negligible levels of
OX2R occupancy by GSK1059865, or functionally meaningful
contributions of the OX1R is an aspect that deserves further
consideration. However, the difference in the cortical effects of the
two compounds in terms of both magnitude and spatial extension
is large, and strongly support the conclusion of a preferential
cortical control by the OX2R.
In summary, we mapped the neuronal substrate for the effects of
selective OX1R or OX2R antagonism in the rat, and correlated
the imaging changes with putative behavioural correlates. Our
results reveal an essential contribution of the OX2R in modulating
cortical activity and the sleep/wake cycle. Conversely, the
subcortical pattern observed with GSK1059865 is suggestive of a
striatal involvement in the control of reward-function and goal-
oriented behaviours by the OX1R.
Figure 6. Sleep-promoting effects of selective OX1R or OX2R antagonism. Sleep-promoting effects (NREM, REM and total sleep time) of
selective OX1R (Left; GSK1059865, 5 and 25 mg/kg i.p.) or OX2R antagonism (Right; JNJ-10397049; 5, 25, and 50 mg/kg) versus vehicle. Data are
expressed in minutes and are represented as means 6 S.E.M. Values were rebinned in 1-hour intervals to cover the whole 5-hour time-window
recorded. (*, P,0.05 and **, P,0.01, treatment versus vehicle, on one-way ANOVA followed by Newmann-Keuls test). Doses that produced
statistically significant effects are indicated in parenthesis above the corresponding time-point.
doi:10.1371/journal.pone.0016406.g006
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Ethics Statements
All the works involving animals were carried out in accordance
with European directive 86/609/EEC governing animal welfare
and protection, which is acknowledged by Italian Legislative
Decree no. 116, 27 January 1992, and were reviewed and
approved by the GlaxoSmithKline Committee on Animal
Research & Ethics (CARE) under protocol #20094 according to
the company Policy on the Care and Use of Laboratory Animals.
Drugs
GSK1059865 and JNJ10397049 were synthesised by the GSK
department of medicinal chemistry.
In vitro potency and receptor specificity
The in vitro potencies of GSK1059865 and JNJ10397049 at rat
orexin receptors were determined using a method previously
described [40]. Briefly, RBL cells stably expressing either rat
OX1R or OX2R receptor were seeded in 96-well plates (3610
4 or
1.5610
4 for OX1R and OX2R study, respectively) and supple-
mented with medium containing 1 mCi per well of [
3H]-myo-
inositol 16 hours prior to the beginning of the assay. Cells were
then washed with the assay buffer (1X HBSS buffer, 20 mM
HEPES pH 7.4, 0.1% BSA, 10 mM LiCl) and pre-incubated for
30 minutes at 37uC with different concentrations of JNJ10397049
(0.333–33.3 mM and 10 nM-0.333 mM at rat OX1R and rat
OX2R, respectively) or GSK1059865 (0.1–33.3 nM and 0.1–
3.33 mM at rat OX1R and rat OX2R, respectively). Orexin-A
concentration-response curves (from 10 mM to 0.1 nM) were
determined in the presence of LiCl 10 mM and 0.1% Bovine
Serum Albumine over a 60-minute time-window. After cell lysis
(0.1 M ice-cold formic acid), 20 ml of the supernatant were placed
in 96 well Optiplate containing 1 mg/well Ysi RNA beads
(Amersham) and shaken for 1 h at room temperature. After 2 h at
4uC, plates were read with a Packard TopCount scintillation
counter. Data were analyzed with GraphPad prism (v.5.0)
software. Antagonist potency values (pKB) were determined by
using the operational model for apparent non surmountable
compounds, or by applying Schild’s analysis for compounds
displaying surmountable profiles [41,42]. pKB values together with
corresponding 95% of confidence interval were calculated from
three independent experiments.
Receptor specificity for GSK1059865 was measured in a
CEREP/Bioprint
TM (CEREP, Redmond, WA) binding assay of
113 receptors, ion channels and transporters, where the drug was
tested at a dose of 1 mM. The selectivity panel consisted of the
following receptors (human isoforms): A1,A 2A,A 3, a1 (non-
selective), a2 (non-selective), b1, b2,A T 1,A T 2, BZD (central), BZD
(peripheral), B1,B 2, CGRP, CB1,C B 2, CCKA (CCK1), CCKB
(CCK2), CRF, D1,D 2,D 3,D 4,D 5, ETA, ETB, GABA (non-
selective), GAL1, GAL2, AMPA, Kainate, NMDA, Glycine
(strychnine-insensitive), PDGF, CXCR2 (IL-8B), TNF-a, CCR1,
CCR2, CCR3, Ghrelin (GHS), H1, H2, H3, ILTB4 (BLT1),
LTD4 (CysLT1), MC4, MT1,M 1,M 2,M 3,M 4,M 5,N K 1,N K 2,
NK3,Y 1,Y 2,N T 1 (NTS1), NmU2, N (neuronal) (a-BGTX-
insensitive) (a4b2), d2 (DOP), k(KOP), m (MOP) (agonist site),
ORL1 (NOP), PACAP (PAC1), PPARc, PAF, PCP, EP4, TXA2/
PGH2, (TP) –platelets, IP (PGI2), P2X,P 2Y, 5-HT1A, 5-HT1B,5 -
HT1D, 5-HT2A, 5-HT2B (agonist site), 5-HT2C, 5-HT3, 5-HT4,5 -
HT5A, 5-HT6, 5-HT7, s(non-selective), sst (non-selective), Gluco-
corticoid (GR), Estrogen, Progesterone (PR), Androgen (AR),
TRH1 (M), UT1, VIP1 (VPAC1), V1a, V2,Ca
2+ channel (L, DHP
site), Ca
2+ channel (L, diltiazem site) (benzothiazepines), Ca
2+
channel (L, verapamil site) (phenylalkylamines), Ca
2+ channel (N),
K
+ ATP channel, K
+ V channel, SK
+ Ca channel, Na channel
(site 2), Cl channel, NE transporter, DA transporter, GABA
transporter, Choline transporter (CHT1), 5-HT transporter.
Selectivity data for JNJ10397049 have been described in previous
reports [9,compound 9 in 14] where the drug was tested at 10 mM
Figure 7. Effect of the OX1R antagonist on cocaine induced CPP. Effect of vehicle (veh) or GSK1059865A on the expression of cocaine-
induced CPP response. Acute administration of 10 and 30 mg/kg i.p. of GSK1059865 significantly decreased the expression of the CPP response to
cocaine compared to vehicle at 10 mg/kg and 30 mg/kg i.p. (** p,0.01 vs. Vehicle; ANOVA and Student-Newman-Keuls test). Times spent in the
cocaine-paired and cocaine-unpaired chambers on test day are shown as means 6S.E.M. (## p,0.01 versus Vehicle-Cocaine + Vehicle on test day,
Student’s u npaired t test).
doi:10.1371/journal.pone.0016406.g007
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receptors (Cerep ExpressProfile).: A1,A 2A,A 3, a1 (non-selective),
a2 (non-selective), b1, b2,C B 1,D 1,D 2, GABA (non-selective),
BZD, Cl-channel (GABA-gated), H1,H 2,M T 1,M 1,M 2,M 3, TP,
5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT3, 5-HT5A, 5-HT6,5 -
HT7,A T 1,B 2, CCR1,CXCR2, CCK1,E T A, GAL2, MC4, NK2,
NK3,Y 1,Y 2,N T 1 (NTS1), d2 (DOP), k(KOP), m(MOP) (agonist
site), NOP, sst, VPAC1,V 1a,Ca
2+ channel (L, DHP site), Ca
2+
channel, K
+ (V channel), SKCa channel, Na channel (site 2), DA
transporter, NE transporter, 5-HT transporter.
Pharmacokinetics and bioanalysis
The pharmacokinetic of GSK1059865 was determined follow-
ing intra-peritoneal administration to male CD rats (250–350 g,
Charles River, Italy) as previously described [43]. GSK1059865
was dissolved in a vehicle composed of 5% dimethyl-sulphoxide/
1.5% HPMC/0.15% SLS (Sodium Lauryl Sulphate) and contain-
ing 10% (w/v) D-Mannitol. This vehicle was also used for
JNJ10397049 throughout the study. The compound was admin-
istered intraperitoneally at 10 or 30 mg/kg (vehicle volume 4 mL/
kg, N=3 per dose). Blood samples were collected via femoral vein
at intervals up to 5 h after administration. Brain samples were
collected at the end of the experiment. The concentration of
GSK1059865 was determined using a method based on protein
precipitation followed by HPLC-MS/MS analysis. Non-compart-
mental pharmacokinetic parameters were obtained from the blood
concentration-time profiles using the software package WinNonlin
v.4.0 (Pharsight Corp. Mountain View, CA, USA). In vitro blood
and brain unbound fractions were determined incubating
GSK1059865 at 1 mg/mL in a 96-well equilibrium dialysis
apparatus (HTDialysis, Gales Ferry, CT) using the method
described by Kalvass and colleagues [44]. Theoretical receptor
occupancy for GSK1059865 was calculated applying the law of
mass action as described in greater detail elsewhere [43,45]:
tRO(%)~
DReceptorCompartment

Kdz DReceptorCompartment
 x100
assuming unbound blood and brain concentration corresponding
to average exposure (Caverage.). Pharmacokinetic parameters are
expressed as mean 6 standard error of the mean.
Pharmacological Magnetic Resonance Imaging
The studies were performed on Male Sprague-Dawley rats
(Charles River, weight range 250–344 grams). Animals had free
access to standard rat chow and tap water and were housed in
groups of 5. Room temperature (20–22uC), relative humidity (45–
65%) and dark-light cycles (12 h each, lights on at 06:00 h) were
automatically controlled.
Animal preparation/monitoring and MRI acquisition param-
eters have been extensively described in previous papers
[25,46,47]. Briefly, rats were anaesthetized with 3% halothane,
tracheotomised and artificially ventilated with a mechanical
respirator under neuromuscular blockade (D-tubocurarine
0.25 mg/kg/h). The left femoral artery and vein were cannulated
for compound administration and continuous measurement of
arterial blood pressure (MABP). A cannula was also inserted
intraperitoneally for drug pre-treatment. After surgery the rat was
secured on a custom-made holder and halothane level set to 0.8%.
The ventilation parameters were adjusted to maintain physiolog-
ical arterial blood gases (paCO2 and paO2) levels according to
measurements performed prior to and at the end of the fMRI time
series acquisition (Table S1). No statistically significant difference
between pre- and post-acquisition paCO2 values for each of the
amphetamine-challenged groups was found (one way ANOVA,
p.0.68). Moreover, linear regression analysis did not show
significantcorrelation between the amplitudeofthe relative cerebral
blood volume (rCBV) response to amphetamine (expressed as 4–
20 min post-injection average in the somatosensory cortex) and
paCO2 levels, when these were expressed as individual measure-
ments (P.0.17, r,0.54), or pre- and post- acquisition difference
(P..67, r,.18). PaO2 levels were higher than 90 mmHg in all
subjects, corresponding to . 98% hemoglobin saturation.
The body temperature of all subjects was maintained within
physiological range (3760.8uC) throughout the experiment, by
using a water heating system incorporated in the stereotactic
holder. MABP was monitored continually through the femoral
artery at a sampling rate of 50 Hz and re-binned on 42 s bins to
match temporal resolution of phMRI timeseries. At the end of the
experiment, the animals were euthanized with an overdose of
anaesthetic followed by cervical dislocation.
rCBV measurement
MRIdata were acquired using a BrukerAvance4.7Teslasystem,
a 72 mm birdcage resonators for radiofrequency pulse transmit and
a curved quadrature receive coil. The MR acquisition for each
subject comprised T2-weighted anatomical images using the RARE
sequence (TReff =5000 ms, TEeff =76 ms, RARE factor 8, FOV
40 mm, 2566256 matrix, 16 contiguous 1 mm slices) followed by a
time series acquisition with the same spatial coverage and similar
parameters (TReff =2700 ms, TEeff =110 ms, RARE factor 32),
but with a lower in-plane spatial resolution (1286128) giving a
functional pixel volume of ,0.1 mm
3. Two successive scans were
averaged for a resulting time resolution of 42 s. Total MRI time-
series acquisition time was 77-min (110 repetitions) for all subjects.
Following five reference images, 2.67 ml/kg of the blood pool
contrast agent Endorem (Guerbet, France) was injected so that
subsequent signal changes would reflect alterations in relative
cerebral blood volume (rCBV) [28]. After an equilibration period of
15 min (22 images) each subject received an intraperitoneal pre-
treatment followed by an acute intravenous challenge with D-
amphetamine (or vehicle) 30 min later (image 62).
GSK1059865 and JNJ10397049 were used in two independent
experiments.
OX1R antagonist study (GSK1059865). Rats were
randomly assigned to one of the two following groups:
- intraperitoneal (IP) pretreatment with vehicle (4 ml/kg) followed
by intravenous challenge with D-amphetamine sulphate (SIG-
MA, 1 mg/kg, 1 ml/rat IV) 30 min later (group #1; N=10)
- IP pretreatment with GSK1059865A (30 mg/kg) followed by
intravenous challenge with D-amphetamine sulphate (1 mg/
kg) 30 min later (group #2, N=8)
OX2R antagonist study (JNJ10397049). Rats were
randomly assigned to one of the two following groups:
- IP pretreatment with vehicle (4 ml/kg) and intravenous
challenge with D-amphetamine sulphate (1 mg/kg, 1 ml/rat
IV) 30 min later (group #3, N=9)
- IP pretreatment with JNJ10397049 (50 mg/kg) and intrave-
nous challenge with D-amphetamine sulphate (1 mg/kg)
30 min later (group #4, N=8)
An additional group of subjects pre-treated with vehicle and
challenged with saline (1 ml/kg) was acquired to serve as reference
rCBV baseline for both studies (group #5, N=6).
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injection was followed by administration of 0.4 ml of saline to flush
the intravenous line.
The dose chosen for D-amphetamine sulphate was based on
previously published in vivo studies [18]. This dose elicits robust
and reproducible brain activation without producing blood
pressure alterations exceeding the cerebral blood flow autoregu-
latory range under halothane anaesthesia [19,48], and is
comparable to the dose that was shown to increase Fos expression
in orexin neurons [16]. The dose used for this study does not
induce ‘‘ceiling’’ rCBV responses, as previous studies using an
identical protocol showed region-specific potentiation of D-
amphetamine responses upon prior pharmacological modulation
of dopamine receptors [18,20].
phMRI data analysis
rCBV time series image data for each experiment were analyzed
within the framework of the general linear model (GLM) to obtain Z
statistic maps [49]. The maps thus obtained were used to guide the
selection of activated regions for subsequent volume of interest
(VOI)–based quantification and comparison of efficacy of treatments.
Signal intensity changes in the time series were converted into
fractional rCBV on a pixel-wise basis, using a constrained
exponential model of the gradual elimination of contrast agent
from the blood pool [50]. Individual subjects in each study were
spatially normalized by a 9-degree–of-freedom affine transforma-
tion mapping their T2-weighted anatomical images to a stereotaxic
rat brain MRI template set and applying the resulting transfor-
mation matrix to the accompanying rCBV time series.
rCBV time series for the amphetamine challenge (groups 1–4)
were calculated covering 8.4 minute (12 timepoints) pre-challenge
baseline and 21.0 minute (30 timepoints) post-challenge windows,
normalized to a common injection time point. Image based time
series analysis was carried out using FEAT (FMRI Expert Analysis
Tool) Version 5.63, part of FSL (FMRIB’s Software Library, www.
fmrib.ox.ac.uk/fsl) with 0.8 mm spatial smoothing (<2.56 in-
plane voxel dimension) and using a model function identified by
Wavelet Cluster Analysis (WCA) across all animals in the cohort,
capturing the temporal profile of the signal change induced by the
amphetamine challenge in each group [51]. The design matrix
also included the temporal derivative of this regressor and a linear
ramp (both orthogonalised to the regressor of interest) with the aim
to capture additional variance due to slight deviations in individual
subjects or brain regions from the signal model time course as
described more in detail elsewhere [52]. The model functions
obtained for the two studies were very similar and captured very
well the sustained positive rCBV changes produced by the drug
challenge (Figure S1). The coefficients of the model function thus
provided a map of rCBV response amplitude for each injection in
each subject. Higher-level group comparisons were carried out
using FLAME (FMRIB’s Local Analysis of Mixed Effects); Z
(Gaussianised T/F) statistic images were thresholded using clusters
determined by Z.2.33 (study 1) or Z.1.96 (study 2) and a
corrected cluster significance threshold of p=0.01 [49,53]. To rule
out the presence of significant short-lived contributions to the
pattern of activation produced by amphetamine in the different
groups, we performed an additional GLM analysis using a
regressor that we identified retaining only high temporal frequency
components in the WCA analysis with the aim to capture subtle
short-lived responses similar to the transient rCBV depression
produced by intravenous vehicle. This analysis did not highlight
any significantly activated or deactivated voxel vs. vehicle-vehicle
baseline for any of the groups analyzed (Z.1.6, cluster correction
p=0.05).
VOI time courses for the amphetamine challenge were
extracted from unsmoothed rCBV time series data using a 3D
digital reconstruction of a rat brain atlas [54] co-registered with
the MRI template, using software written in IDL (Research
Systems Inc., Boulder, Colorado). A list of the VOIs examined and
their anatomical definitions can be found in [25]. For each VOI
time course, the average rCBV over a 6 min time window
covering the peak of the response to amphetamine (4–10 min post-
injection) was used as a summary statistic of the relative change.
The effect of OX1R antagonist pretreatment on the magnitude of
average rCBV in different VOIs was assessed by a one-way
ANOVA followed by Fishers’s LSD test versus vehicle-amphet-
amine (groups 1 and 3, respectively). Results are quoted and
displayed as mean 6 SEM.
As subjects received the pre-treatment during the phMRI time-
series acquisition, VOI time-courses of pre-treatment per se were
examined to exclude the presence of rCBV ‘‘ceiling’’ or ‘‘floor’’
effects that might have influenced or prevented the subsequent
response to amphetamine. To this end, rCBV time-courses were
also calculated for the pre-treatment over a time-window covering
5.6 minutes (8 timepoints) pre-injection baseline and 25.2 minutes
(36 timepoints) post-injection window normalized to a common
injection time point. VOI timecourses were extracted from
unsmoothed rCBV time series in the same regions examined for
the amphetamine challenge.
Sleep recording and analysis
Male Sprague Dawley rats (275–300 g, Charles River Italy) were
housed singly on 12 h light dark cycle (15:00–03:00 light) one week
prior to surgery. Access to food and water was allowed ad libitum.I n
order to collect the biopotential signals, a miniature multichannel
telemetric transmitter (TL10M3-F40-EET, Data Sciences Int.) was
implanted intraperitoneally into the animals. To allow recording of
cortical electroencephalogram (EEG), two electrodes were fixed
permanently to the skull with dental cement. The electrodes were
placed in direct contact with the dura mater through two drilled holes
on the fronto-parietal region. Two additional electrodes were fixed
to the skeletal muscles of the neck, to allow electromyogram (EMG)
recordings. Although implanted animals demonstrated a normal
behavioural repertoire immediately after surgery, a three weeks
time period was allowed prior to experimental utilisation in order to
allow normal sleep patterns to be re-established.
For the duration of the test period freely moving animals
remained in their home cages on individual receivers. EEG and
EMG signals were recorded continuously using DSI DataquestH
A.R.T. The EEG trace, divided into ten second epochs, was
digitally transformed (FFT transformation) to provide the power
spectra of d, h, a and b bands so to distinguish three different
activity patterns in the rat (awake, NREM sleep and REM sleep).
The markers assigned by the automated scoring system (Sleep
stageH, DSI) were transferred to the EEG digital signal and
subsequently confirmed by visual examination of the EEG and
EMG traces by trained operators, blind to the drug treatment.
Analysis of sleep parameters included: time spent wake, NREM
sleep, REM sleep and total sleep time (TST).
Drug studies were carried out according to a randomised paired
crossover design where each animal received control and drug
treatments in separate experimental sessions. Animals were treated
with GSK1059865 or JNJ10397049 or vehicle six hours into the
dark phase (Circadian time (CT) 18). At this point in the light/
dark cycle the concentration of the orexin-A peptide is high, thus
maximising the pharmacological window of effective antagonism
[21]. Recordings were made over a 5-hour test period. Results
were expressed as mean value 6 S.E.M. Statistical analysis was
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Dunnett’s test (summary measurements) or Newmann-Keuls
(individual time-points in NREM and REM timecourses).
Conditioned place –preference (CPP)
The studies were performed on Male Sprague-Dawley rats
(155–165 g upon arrival, Charles River, Como, Italy). Animals
were housed two per cage and kept on a 12 hours lights on/
12 hours lights off schedule and food and water were available ad
libitum. An automated, three-chambered CPP apparatus was used
as previously described [55]. The two pairing chambers of the
apparatus were identical in dimensions and separated by
removable plexiglass guillotine doors. The pairing chambers were
fitted with different visual and tactile cues. The cues were balanced
to avoid the development of side preferences prior to conditioning.
Each of the pairing chambers had an infrared micro-beam that
was wired to an automatic timer to measure the time spent in each
chamber.
CPP acquisition and expression were both established and
assessed as previously
described [55]. Briefly, animals were habituated to the
experimental room and handled for 5 days prior to the CPP
experiments. Prior to the start of the CPP experiments, the
animals were allowed to freely explore the apparatus for 15 min.
Animals were then randomly divided into 6 groups (n=10 each).
One group received 4 pairings (one injection per day) with vehicle
(water, vehicle-vehicle), while the remaining 5 groups received 4
pairings with vehicle followed by 15 mg/kg i.p. of cocaine (vehicle-
cocaine). The animals were confined to one of two conditioning
chambers for 30 min during each pairing session. On the test day
the animals received either vehicle or GSK1059865A (3, 10 or
30 mg/kg i.p) 30 minutes prior to the behavioural test. The overall
pairing scheme used is described below:
Pairings treatments on the test day
Vehicle-Vehicle Vehicle i.p.
Vehicle-Cocaine Vehicle i.p.
Vehicle-Cocaine 3 mg/kg of GSK1059865 i.p.
Vehicle- Cocaine 10 mg/kg of GSK1059865 i.p.
Vehicle- Cocaine 30 mg/kg of GSK1059865 i.p.
The animals were allowed access to the entire apparatus for
15 min, and the data were expressed as the raw time spent in each
chamber. Statistical analysis was performed with GB-STAT,
version 6.5 (Dynamics Microsystsms, Inc., Silver Spring, MD,
USA, 1997) using a one-way analysis of variance (ANOVA)
followed by a Student- Newmans-Keuls test.
Supporting Information
Figure S1 Time–profile of the temporal components identified
with WCA [52] in groups 1–2 (Regr 1), and 3–4 (Regr 2). The
regressors were used as model function for GLM analysis as
detailed in the methods section.
(TIF)
Figure S2 Temporal profile of mean arterial blood pressure
(MABP) produced by intraperitoneal pretreatment (Left) or
amphetamine challenge (Right); Data are plotted as mean6SEM
within each group. Upper and lower cerebral blood flow
autoregulation range under halothane anaesthesia are illustrated
by dashed lines at 120 and 60 mmHg, respectively [19]; Ox1Rant:
GSK1059865 30 mg/kgi.p.; Ox2Rant:: JNJ1039704950 mg/kg i.p.
(TIF)
Figure S3 Effect of pretreatment on basal CBV in representative
brain regions. Data are plotted as mean6SEM within each group.
Ox1Rant: GSK1059865 30 mg/kg i.p.; [Mt Ctx: primary motor
cortex; SS Ctx: somatosensory cortex; mPFC: medial prefrontal
cortex; Ins Ctx; insular cortex; Thal; thalamus; Hipp: hippocam-
pus].
(TIF)
Figure S4 Effect of pretreatment on basal rCBV in represen-
tative brain regions. Data are plotted as mean6SEM within each
group. Ox2Rant: JNJ10397049 50 mg/kg i.p. [Mt Ctx: primary
motor cortex; SS Ctx: somatosensory cortex; mPFC: medial
prefrontal cortex; Ins Ctx; insular cortex; Thal; thalamus; Hipp:
hippocampus].
(TIF)
Table S1 Abbreviations: PaCO2 - partial pressure of arterial
CO2; Pre and Post: measurements performed prior to and after the
fMRI timeseries, respectively. Values presented as mean 6 SEM.
Ox1ant-: GSK1059865 30 mg/kg i.p.; Ox2ant:: JNJ10397049
50 mg/kg i.p.
(DOC)
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